Colin P.N. Dinney, MD

Peer-Reviewed Articles

1. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2022. PMID: 36404232.
2. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2022. PMID: 36250944.
3. Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP , Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol 40(11):2707-2715, 2022. e-Pub 2022. PMID: 36169695.
4. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP , Kamat AM. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?. BJU Int 130(4):463-469, 2022. e-Pub 2021. PMID: 34854189.
5. Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP , Kamat AM. Reduced Dose BCG in an Era of BCG Shortage: Real-World Experience from a Tertiary Cancer Centre. BJU Int 130(3):323-330, 2022. e-Pub 2021. PMID: 34847263.
6. Mokkapati S, Narayan VM, Manyam GC, Lim AH, Duplisea JJ, Kokorovic A, Miest TS, Mitra AP, Plote D, Anand SS, Metcalfe MJ, Dunner K, Johnson BA, Czerniak BA, Nieminen T, Heikura T, Yla-Herttuala S, Parker NR, Schluns KS, McConkey DJ, Dinney CP . Lentiviral interferon: A novel method for gene therapy in bladder cancer. Mol Ther Oncolytics 26:141-157, 2022. e-Pub 2022. PMID: 35847448.
7. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP , Kamat AM. Reply by Authors. J Urol 208(2):290-291, 2022. e-Pub 2022. PMID: 35770497.
8. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP , Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
9. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP , Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. e-Pub 2022. PMID: 35961847.
10. Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, Dinh KN, Majewski T, Zhang L, Cao S, Tian F, Yao H, Kus P, Chen H, Weinstein JN, Navai N, Dinney CP , Gao J, Theodorescu D, Logothetis C, Guo CC, Wang W, McConkey D, Wei P, Kimmel M, Czerniak B. The origin of bladder cancer from mucosal field effects. iScience 25(7):104551, 2022. e-Pub 2022. PMID: 35747385.
11. Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, Dinh KN, Majewski T, Zhang L, Cao S, Tian F, Yao H, Kus P, Chen H, Weinstein JN, Navai N, Dinney CP , Gao J, Theodorescu D, Logothetis C, Guo CC, Wang W, McConkey D, Wei P, Kimmel M, Czerniak B. Erratum: The origin of bladder cancer from mucosal field effects. iScience 25(7):104715, 2022. e-Pub 2022. PMID: 35811851.
12. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB,Dinney CP , Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2021. PMID: 33935020.
13. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney CP Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2021. PMID: 35039231.
14. Khanna A, Miest T, Sharma V, Campbell R, Hensley P, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Murthy PB, Haber GP, Navai N, Kamat AM,Dinney CP , Lee B, Boorjian SA. Role of Lymphadenectomy During Radical Cystectomy for Non-muscle Invasive Bladder Cancer: Results From a Multi-Institutional Experience. J Urol 207(3):101097JU0000000000002266, 2022. e-Pub 2021. PMID: 34694143.
15. Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CP . Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol 81(3):223-228, 2022. e-Pub 2021. PMID: 34933753.
16. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP , Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2021. PMID: 34920986.
17. Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP , Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Black PC. Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]. Eur Urol Focus. e-Pub 2022. PMID: 35181282.
18. D'Andrea D, Black PC, Zargar H, Dinney CP , Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carrión DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF, Contributors. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol 207(1):101097JU0000000000002190, 2022. e-Pub 2021. PMID: 34445891.
19. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney CP , Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2021. PMID: 35475152.
20. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney, CP , Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol 39(12):4345-4354, 2021. e-Pub 2021. PMID: 34370078.
21. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP , Kamat AM. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
22. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP , Kamat AM. Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. BJU Int 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
23. Bree KK, Hensley PJ, Brooks N, Matulay J, Nogueras-Gonzalez GM, Navai N, Dinney CP , Kamat AM. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World J Urol 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
24. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP , Kamat AM. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):101097JU0000000000001943, 2021. e-Pub 2021. PMID: 34184926.
25. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP , Kamat AM. Reply by Authors. J Urol 206(5):101097JU000000000000194302, 2021. e-Pub 2021. PMID: 34372685.
26. Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP , Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy. J Urol 206(3):101097JU0000000000001784, 2021. e-Pub 2021. PMID: 33872050.
27. Zhou X, Kurywchak P, Wolf-Dennen K, Che SPY, Sulakhe D, D'Souza M, Xie B, Maltsev N, Gilliam TC, Wu CC, McAndrews KM, LeBleu VS, McConkey DJ, Volpert OV, Pretzsch SM, Czerniak BA, Dinney CP , Kalluri R. Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. Mol Ther Methods Clin Dev 22:360-376, 2021. e-Pub 2021. PMID: 34514028.
28. Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney CP , McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol 206(3):548-557, 2021. e-Pub 2021. PMID: 33881933.
29. Kukreja JB, Li R, Narayan VM, Lim A, Seif M, Wang X, Kamat A, Dinney CP , Navai N. Oncologic equipoise between robotic and open radical cystectomy. J Endourol 35(8):1168-1176, 2021. e-Pub 2021. PMID: 33619985.
30. Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CP , Grossman HB, Kamat AM. The Obesity Paradox: Defining the impact of Body Mass Index and Diabetes Mellitus for patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. BJU Int 128(1):65-71, 2021. e-Pub 2020. PMID: 33210440.
31. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CP , Kamat AM. Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design. J Urol 205(6):101097JU0000000000001633, 2021. e-Pub 2021. PMID: 33502236.
32. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CP , Kamat AM. Reply by Authors. J Urol 205(6):1620-1621, 2021. e-Pub 2021. PMID: 33734859.
33. Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CP , Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. e-Pub 2021. PMID: 34186127.
34. D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP , Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int 127(5):528-537, 2021. e-Pub 2020. PMID: 32981193.
35. Wang G, Black PC, Goebell PJ, Ji L, Cordon-Cardo C, Schmitz-Dräger B, Hawes D, Czerniak B, Minner S, Sauter G, Waldman F, Groshen S, Cote RJ, Dinney CP . Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol 39(5):301.e17-301.e28, 2021. e-Pub 2021. PMID: 33563539.
36. Kokorovic A, Westerman ME, Krause K, Hernandez M, Brooks N, Dinney CP , Kamat AM, Navai N. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer 7(2):243-252, 2021. e-Pub 2021. PMID: 34195319.
37. Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP , Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol 39(4):237.e1-237.e5, 2021. e-Pub 2020. PMID: 33308972.
38. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN . Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107-117, 2021. e-Pub 2020. PMID: 33253641.
39. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney CP , Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
40. Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CP , Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med 17(10):1995-2004, 2020. e-Pub 2020. PMID: 32713807.
41. Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP , Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand D, Black PC. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. Eur Urol Focus. e-Pub 2020. PMID: 32771446.
42. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP , Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol 38(7):639.e1-639.e9, 2020. e-Pub 2020. PMID: 32057595.
43. Hwang MJ, Kamat AM, Dinney CP , Czerniak B, Guo CC. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol 154(2):208-214, 2020. e-Pub 2020. PMID: 32253420.
44. Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CP . TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer. Mol Cancer Res 18(6):811-821, 2020. e-Pub 2020. PMID: 32122956.
45. Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, Lee JG, Cogdell D, Zhang M, Yang G, Dadhania V, Choi W, Wei P, Gao J, Theodorescu D, Logothetis C, Dinney CP , Kimmel M, Weinstein JN, McConkey DJ, Czerniak B. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep 10(1):9743, 2020. e-Pub 2020. PMID: 32546765.
46. Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney CP , Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak B. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience 23(6):101201, 2020. e-Pub 2020. PMID: 32521509.
47. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP , Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Bladder Cancer Molecular Taxonomy Group. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 77(4):420-433, 2020. e-Pub 2019. PMID: 31563503.
48. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP , Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. Eur Urol 77(4):436-438, 2020. e-Pub 2020. PMID: 32037144.
49. Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney CP , Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol 38(4):247-254, 2020. e-Pub 2020. PMID: 31953001.
50. Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP , Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care 10(1):25-35, 2020. e-Pub 2018. PMID: 30244203.
51. Liem EIML, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP , Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol 203(2):283-291, 2020. e-Pub 2019. PMID: 31549936.
52. Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP , Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res 26(4):882-891, 2020. e-Pub 2019. PMID: 31712383.
53. Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CP , Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus 6(1):88-94, 2020. e-Pub 2018. PMID: 30033071.
54. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP , Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol 38(1):3.e17-3.e27, 2020. e-Pub 2019. PMID: 31676278.
55. Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP , Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol 37(12):2691-2698, 2019. e-Pub 2019. PMID: 30864005.
56. Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP , Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol 5(12):1-9, 2019. e-Pub 2019. PMID: 31670753.
57. Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP . The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol 37(10):2041-2049, 2019. e-Pub 2018. PMID: 30415317.
58. Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, Lotan Y, Dinney CP , Wei P, Baggerly K, Czerniak B. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus 5(4):664-675, 2019. e-Pub 2018. PMID: 29428551.
59. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CP , Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol 37(6):354.e19-354.e26, 2019. e-Pub 2019. PMID: 30777393.
60. Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP , Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol 2(3):286-293, 2019. e-Pub 2018. PMID: 31200843.
61. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney CP , Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep 27(6):1781-1793.e4, 2019. PMID: 31067463.
62. Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, Dinney CP . Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J 13(2):24-28, 2019. e-Pub 2018. PMID: 30138098.
63. Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney CP , Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep 26(8):2241-2256.e4, 2019. PMID: 30784602.
64. Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney CP , Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol 37(1):51-60, 2019. e-Pub 2018. PMID: 30109483.
65. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP , Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol 37(1):165-172, 2019. e-Pub 2018. PMID: 29882105.
66. Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP , Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol 75(1):8-10, 2019. e-Pub 2018. PMID: 30301695.
67. Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP . Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology 8(5):e1577125, 2019. e-Pub 2019. PMID: 31069136.
68. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP , Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
69. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CP , Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus 4(5):720-724, 2018. e-Pub 2017. PMID: 28753837.
70. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP , Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65, 2018. e-Pub 2018. PMID: 29763719.
71. Farnum JA, Vikram R, Rao A, Bedi D, Dinney CP , Matin SF. Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. J Endourol 32(9):806-811, 2018. e-Pub 2018. PMID: 30014707.
72. Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP , Navai N, Shah JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int 122(1):89-98, 2018. e-Pub 2018. PMID: 29569824.
73. Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP , Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov 25(3):242-250, 2018. e-Pub 2018. PMID: 29557251.
74. Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, Dinney CP , Vrieling A, Tu H. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142(9):1797-1804, 2018. e-Pub 2017. PMID: 29235103.
75. Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP , Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer 26(5):1561-1568, 2018. e-Pub 2017. PMID: 29197959.
76. Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP , Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care 8(1):34-37, 2018. e-Pub 2017. PMID: 28860112.
77. Lian J, Lin SH, Ye Y, Chang DW, Huang M, Dinney CP , Wu X. Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. Oncotarget 9(19):14895-14908, 2018. e-Pub 2018. PMID: 29599914.
78. Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP , Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121(2):244-251, 2018. e-Pub 2017. PMID: 28872778.
79. Tu H, Dinney CP , Ye Y, Grossman HB, Lerner SP, Wu X. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr 107(2):208-216, 2018. PMID: 29529165.
80. Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP , Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol 9(1):81-83, 2018. e-Pub 2017. PMID: 28844850.
81. Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, Zhao H, Tsai MK, Huang M, Dinney CP , Tsao CK, Wu X. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ 360:k134, 2018. e-Pub 2018. PMID: 29386192.
82. van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, Geavlete B, Moldoveanud C, Ene C, Dinney CP , Czerniak B, Schalken JA, Kiemeney LALM, Ribal MJ, Witjes JA, Alcaraz A. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics 10:71, 2018. e-Pub 2018. PMID: 29854012.

Invited Articles

1. Mitra AP, Miest T, Dinney CP . Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol 79(3):428-429, 2021. e-Pub 2020. PMID: 33158662.
2. Konety BR, Narayan VM, Dinney CP . Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context. Urol Clin North Am 47(1):1-4, 2020. PMID: 31757292.
3. Narayan VM, Dinney CP . Intravesical Gene Therapy. Urol Clin North Am 47(1):93-101, 2020. PMID: 31757304.
4. Narayan VM, Lim AH, Dinney CP . Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. Eur Urol 75(6):1034-1035, 2019. e-Pub 2019. PMID: 30833138.
5. Lerner SP, Bajorin DF, Dinney CP , Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2(2):165-202, 2016. e-Pub 2016. PMID: 27376138.
6. McConkey DJ, Choi W, Dinney CP . New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 66(4):609-10, 2014. e-Pub 2014. PMID: 24877661.
7. Dinney CP, Navai N, Wszolek MF. Molecular prognostic factors for bladder cancer: Improving NAC patient selection by integrating prognostic markers into the MIBC treatment paradigm. European Urology Today(Edition 1):17, 2012.
8. Zlotta AR, Cohen SM, Dinney CP , Droller M, van der Kwast TH, van Rhijn BW, Bochner B, Ameil G, Jewett MA. BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. Urol Oncol 28(3):329-33, 2010. PMID: 20439032.
9. McConkey DJ, Dinney CP . Urological cancers. Preface. Cancer Metastasis Rev 28(3-4):267, 2009. PMID: 20013034.
10. Svatek RS, Dinney CP . Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. Eur Urol 56(4):745-6, 2009. PMID: 19995527.
11. Svatek RS, Dinney CP . Words of wisdom. Re: Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Lotan Y, Shariat SF; NMP22 Study Group. BJU Int 2008;101:1362-7. Eur Urol 56(1):217-8, 2009. PMID: 19995517.
12. Svatek RS, Avritscher EB, Elting L, Dinney CP . High risk populations and cystectomy outcomes. J Urol 182(1):10-1. e-Pub 2009. PMID: 19450857.
13. Lamm DL, Dinney CP . Advances in Bladder Cancer Treatment of High-Risk Non-Muscle-Invasive TCC: An Ongoing Debate. Renal & Urology News Part 4, 2008.
14. Black PC, Dinney CP . Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 9(1):55-61, 2008. PMID: 18366975.
15. Black PC, Dinney CP . Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Cancer Metastasis Rev 26(3-4):623-34, 2007. PMID: 17726580.
16. Black PC, Brown GA, Grossman HB, Dinney CP . Neoadjuvant chemotherapy for bladder cancer. World J Urol 24:531-42, 2006. PMID: 17115230.
17. Black PC, Brown GA, Dinney CP . Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. Curr Opin Urol 16:344-9, 2006. PMID: 16905980.
18. Kamat AM, Dinney CP . A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3:472-3, 2006. PMID: 16964186.
19. Dinney CP . Therapy of invasive bladder cancer. Urology 67:56-9; discussion 60-1, 2006. PMID: 16530078.
20. Adam L, Kassouf W, Dinney CP . Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am 32(2):239-46, vii, 2005. PMID: 15862621.
21. Highshaw RA, McConkey DJ, Dinney CP . Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol 14(5):295-300, 2004. PMID: 15300150.
22. Grossman HB, Dinney CP . If cystectomy is insufficient, what is an urologist to do?. Urol Oncol 21(6):475-8, 2003. PMID: 14693276.
23. Canfield SE, Dinney CP , Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am 30(4):791-802, 2003. PMID: 14680315.
24. Bellmunt J, Hussain M, Dinney CP . Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46 Suppl:S85-104, 2003. PMID: 12850530.
25. Dinney CP , Bermejo CE. Treating bladder cancer and getting back in the game. Coping, 2003.
26. Rosser CJ, Benedict WF, Dinney CP . Gene therapy for superficial bladder cancer. Expert Rev Anticancer Ther 1(4):531-9, 2001. PMID: 12113085.
27. Izawa JI, Dinney CP . The role of angiogenesis in prostate and other urologic cancers: a review. Cmaj 164(5):662-70, 2001. PMID: 11258215.
28. Hsieh JT, Dinney CP , Chung LW. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 27(1):103-13, ix, 2000. PMID: 10696249.
29. Grossman HB, Dinney CP . Markers of bladder cancer: state of the art. . Urol Oncol 5:3-10, 2000.
30. Hall CM, Dinney CP . Radical cystectomy for stage T3b bladder cancer. Semin Urol Oncol 14(2):73-80, 1996. PMID: 8734734.
31. Millikan R, Dinney CP . The role of chemotherapy in the management of the patient with T3b bladder cancer. Semin Urol Oncol 14(2):81-5, 1996. PMID: 8734735.
32. Dinney CP . Optimal treatment for androgen-dependent prostate tumors. Cancer Bull 45:418-423, 1993.
33. Dinney CP , Norman RW. Contralateral pleural effusion secondary to nonmetastatic renal cell carcinoma. J Urol 143(5):1002-3, 1990. PMID: 2329586.

Editorials

1. Duplisea JJ, Dinney CP . Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy"?. Expert Rev Anticancer Ther 19(7):543-545, 2019. PMID: 31164019.
2. Dinney CP . Bladder cancer. Urol Oncol 26(5):479-80, Sep-Oct, 2008. PMID: 18774458.

Abstracts

1. Lim A, Narayan VM, Seif M, Matulay JT, Dinney CPN, Navai N. Comparative analysis of biopsy proven lymph node positive bladder cancer patients to those with biopsy proven lymph node negative disease prior treatment. J Clin Oncol 37(7S), 2019.
2. Kukreja JB, Li R, Seif M, Wang X, Kamat AM, Dinney CPN, Pisters LL, Navai N. A comparison of pathologic and intermediate term oncologic outcomes following open and robotic radical cystectomy. J Clin Oncol 37(7S), 2019.
3. Narayan VM, Seif M, Lim A, Li R, Qiao W, Hwang H, Dinney CPN, Navai N. A comprehensive assessment of postoperative complications in female patients undergoing robot versus open radical cystectomy. J Clin Oncol 37(7S), 2019.
4. Narayan VM, Lim A, Mokkapati S, Manyam GC, Plote D, Sundi D, Choi W, Dinney CPN. Let-7f microRNA expression within established bladder cancer subtypes and upregulation with recombinant interferon-alpha. J Clin Oncol 37(7S), 2019.
5. Choi S, Campbell MT, Shah AY, Navai N, Kamat AM, Dinney CPN, Nguyen Q, Siefker-Radtke AO. Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer. J Clin Oncol 37(7S), 2019.
6. Mokkapati S, Duplisea JJ, Plote D, Narayan VM, Lim A, Metcalfe MJ, Dunner K, Czerniak B, Nieminen T, Heikuri T, Yla-Herttuala S, Parker N, Schluns K, McConkey DJ, Dinney CPN. Lentiviral interferon: A novel method for gene therapy in bladder cancer. J Clin Oncol 37(7S), 2019.
7. Gao J, Siefker-Ratke AO, Navai N, Campbell MT, Slack R, Guo C, Kamat AM, Matin SF, Papadopoulos JN, Araujo JC, Shah AY, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Dinney CPN, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy. J Clin Oncol 36, 2018.
8. Zhang X, Sun M, Geng Y, Dinney CPN, Popat UR, Champlin RE, Valero V, Tripathy D, Hedberg A, Stroehlein JR, Edwards BJ. Malnutrition and overall survival in older patients with cancer. J Clin Oncol 36, 2018.
9. Edwards BJ, Zhang X, Pang L, Sun M, Geng Y, Hedberg A, Tripathy D, Champlin R, Popat UR, Dinney CPN. Vitamin D deficiency in older cancer patients with solid tumors, effect on overall survival. J Clin Oncol 36, 2018.
10. Li R, Tabayoyong W, Guo C, Gonzalez GN, Navai N, Growman HB, Dinney C, Kamat A. BCG UNRESPONSIVE DEFINITION SUPERSEDES DISTINCTION BETWEEN REFRACTORY AND RELAPSING DISEASE. J Urol 199(4):e1233, 2018.
11. Li R, Kukreja J, Petros F, Campbell M, Nguyen J, Gonzalez GN, Kamat A, Pisters L, Dinney C, Navai N. THE ROLE OF METASTATIC BURDEN IN CYTOREDUCTIVE/CONSOLIDATIVE RADICAL CYSTECTOMY. J Urol 199(4):e810-e811, 2018.
12. Kukreja JB, Navai N, Mery M, Incalcaterra J, Kamat A, Dinney C. DRIVERS OF COST FOR AN EPISODE OF CARE IN RADICAL CYSTECTOMY. J Urol 199(4):e1025, 2018.
13. Li R, Tabayoyon W, Guo C, Gonzalez GN, Navai N, Grossman HB, Dinney C, Kamat A. IMPORTANCE OF MAINTENANCE BCG INCLUSION FOR THE BCG UNRESPONSIVE CLASSIFICATION. J Urol 199(4):e1122-e1123, 2018.
14. Petros F, Qi Y, Choi W, Li R, Su X, Guo C, Dinney C, McConkey D, Matin S. GENOMIC ANALYSIS OF SAME-PATIENT METACHRONOUS UPPER-TRACT AND BLADDER UROTHELIAL CARCINOMA. J Urol 199(4):e215-e216, 2018.
15. Duplisea J, Mokkapati S, Metcalfe M, Dunner K, Czerniak B, Nieminen T, Heikura T, Yla-Herttuala S, Parker N, McConkey D, Dinney C. LENTIVIRAL INTERFERON: A NOVEL METHOD FOR GENE THERAPY IN BLADDER CANCER. J Urol 199(4):e712-e713, 2018.
16. Duplisea J, Metcalfe M, Sundi D, Ferguson J, Li R, Pretzsch S, Kamat A, Navai N, Shah J, Bondaruk J, Czerniak B, Choi W, McConkey D, Black P, Dinney C. REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES. J Urol 199(4):e616, 2018.
17. Duplisea J, Seif M, Tabayoyong W, Aloia T, Pretzsch S, Kamat A, Pisters L, Pettaway C, Davis J, Grossman HB, Shah J, Papadopoulos J, Graber W, Westney L, Navai N, Dinney C. THE UTILITY OF THE ACS NSQIP SURGICAL RISK CALCULATOR IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: OPEN AND ROBOTIC TECHNIQUES. J Urol 199(4):e621, 2018.
18. Li R, Baack Kukreja J, Petros FG, Campbell MT, Nguyen J, Norgueras-Gonzalez GM, Kamat AM, Pisters LL, Dinney CPN, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. J Clin Oncol 36(6S), 2018.
19. Li R, Metcalfe MJ, Tabayoyong W, Guo C, Nogueras-Gonzalez GM, Navai N, Grossman HB, Dinney CPN, Kamat AM. Using grade of tumor recurrence after BCG to guide further therapy. J Clin Oncol 36(6S), 2018.
20. Choi W, Plimack ER, Siefker-Radtke A, Dinney CPN, McConkey DJ. A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. J Clin Oncol 36(6S), 2018.
21. Petros FG, Qi Y, Choi W, Li R, Su X, Guo C, Dinney CPN, McConkey D, Matin SF. Genomic analysis of same-patient metachronous upper-tract and bladder urothelial carcinoma. J Clin Oncol 36(6S), 2018.
22. Sundi D, Choi W, Jayaratna IS, McConkey DJ, Dinney CPN. Differential expression of FOXF1 in bladder cancer metastases and association with established bladder cancer subtypes. J Clin Oncol 34(2S), 2018.
23. Zhang X, Sun M, Shah JB, Dinney CPN, Popat UR, Champlin RE, Valero V, Tripathy D, Hedberg AM, Edwards BJA. Prevalence of vitamin D insufficiency and falls in older cancer patients. J Clin Oncol 35(5S), 2018.
24. Metcalfe M, Ferguson J, Li R, Lianchun X, Navai N, Kamat A, Shah J, Dinney C. CLINICAL AND PATHOLOGICAL OUTCOMES FOR PATIENTS WITH HIGH RISK T1HG BLADDER CANCER MANAGED WITH EITHER UPFRONT CYSTECTOMY OR PRIMARY BCG AND DELAYED CYSTECTOMY. J Urol 197(4):e-903-e904, 2017.
25. Metcalfe M, Compton Z, Li R, Ferguson J, Sundi D, Nguyen J, Kamat A, Shah J, Dinney C, Navai N. COMPARISON OF TOTAL 90 DAY COSTS FOR OPEN VERSUS ROBOTIC CYSTECTOMY. J Urol 197(4):e672-e673, 2017.
26. Zargar H, Shah JB, Fransen van de Putte EE, Potvin KR, Zargar-Shoshtari KZ, van Rhijn BW, Daneshman S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W, Zargar H. DOSE DENSE MVAC PRIOR TO RADICAL CYSTECTOMY: A RETROSPECTIVE MULTI-INSTITUTIONAL EXPERIENCE. J Urol 197(4):e773, 2017.
27. Zargar H, Shah JB, Fransen van de Putte EE, Potkin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshman S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Fairey AS, Kovac E, Krabbe L, Cookson MS, Jacobsen N, Gandhi N, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Seah, J, Ercole CE, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Grivas P, Stephenson AJ, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Black PC, Kassouf W. DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE. J Urol 197(4):e773-e774, 2017.
28. Baack Kukreja J, Ismaeel N, Navai N, Kamat AM, Dinney CPN, Shah JB. Outcomes and survival in nonbilharzial pure squamous cell bladder cancer in patients undergoing curative radical cystectomy. J Clin Oncol 35(6S), 2017.
29. Baack Kukreja J, Chang CM, Chen TY, Shi Q, Wang XS, Navai N, Kamat AM, Dinney CPN, Shah JB. Measuring and improving symptom burden in radical cystectomy patients undergoing traditional care compared to enhanced recovery. J Clin Oncol 35(6S), 2017.
30. Baack Kukreja J, Change CM, Seif M, Navai N, Kamat AM, Dinney CPN, Shah JB. Does liposomal bupivacaine use intraoperatively decrease postoperative narcotic use in radical cystectomy patients?. J Clin Oncol 35(6S), 2017.
31. Baack Kukreja J, Podolnick JM, Wang X, Chen HC, Navai N, Kamat AM, Dinney CPN, Shah JB. Association of presurgery neutrophil-to-lymphocyte ratio with survival outcomes in patients with urothelial carcinoma treated without neoadjuvant chemotherapy and with radical cystectomy. J Clin Oncol 35(6S), 2017.
32. Baack Kukreja J, Podolnick JM, Wang X, Chen HC, Navai N, Kamat AM, Dinney CPN, Shah JB. Association of preoperative neutrophil-to-lymphocyte ratio with survival outcomes in patients undergoing radical cystectomy, regardless of neoadjuvant chemotherapy status. J Clin Oncol 35(6S), 2017.
33. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Dinney CPN, Navai N, Shah JB, Kamat AM. Clinical and pathological outcomes for patients with T1HG bladder cancer managed with upfront cystectomy with or without neoadjuvant chemotherapy and the impact of the MDACC high-risk features. J Clin Oncol 35(6S), 2017.
34. Boorjian SA, Shore ND, Canter D, Ogan K, Karsh LI, Downs T, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb R, Krupski T, Lerner SP, Woods M, Inman BA, Milowsky MI, Parker N, Sawautz D, Dinney CPN. Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study. J Clin Oncol 35(6S), 2017.

Book Chapters

1. Svatek RS, Kamat AM, Siefker-Radtke A, Dinney CP . Bladder Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer Science+Business Media: New York, 143-152, 2013.
2. Siefker-Radtke A, Dinney CP , Czerniak B, Millikan R. Bladder Cancer. In: M. D. Anderson Manual of Medical Oncology. 2nd ed. McGraw-Hill: New York, 925-943, 2011.
3. Steinberg JR, Dinney CP , Grossman HB. Screening, early detection, and prevention of bladder cancer. In: Comprehensive Textbook of Genitourinary Oncology, Third Edition. Lippincott, Williams & Wilkins: Philadelphia, 403-410, 2006.
4. Kassouf W, Bochner BH, Dinney CP . Targeted therapy for bladder cancer. In: Textbook of Bladder Cancer. Taylor & Francis: United Kingdom, 695-710, 2006.
5. Wood CG, Dinney CP . Genitourinary cancer. In: M.D. Anderson Surgical Oncology Handbook, Edition 4. 4th. Lippincott Williams & Wilkins: Baltimore, Maryland, 495-518, 2006.
6. Siefker-Radtke A, Czerniak B, Dinney CP . Uncommon cancers of the bladder. In: Textbook of the Uncommon Cancer, 3rd ed. 3rd ed. John Wiley and Sons: New York, 18-26, 2006.
7. Sweeney P, Dinney CP ,Droller MJ. Molecular pathogenesis of proliferative and progressive (invasive) urothelial cancer development. In: American Cancer Society Atlas of clinical Oncology Urothelial Tumors. BC Decker, Inc, 44-57, 2004.
8. Huang S, Dinney CP . Genitourinary cancer. In: M. D. Anderson Surgical Oncology Handbook. Lippincott Williams & Wilkins, 425-444, 2003.
9. Canfield SE, Dinney CP , Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. In: The Urologic Clinics of North America. Follow-up Strategies and Management of Recurrence in Urologic Oncology. W. B. Saunders Company, 791-802, 2003.
10. Pettaway C, Dinney CP. Urologic and male genital cancer. Section F: Penile and urethral cancer. In: Clinical Oncology. American Cancer Society, 2000.
11. Delworth M, Dinney CP . Genitourinary cancer. In: M. D. Anderson Handbook of Surgical Oncology. Little, Brown and Company, 308-325, 1999.
12. Dinney CP , Pisters L, von Eschenbach AC. Cryoablation for prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams & Wilkins, 828-837, 1998.
13. Dinney CP , Fidler I. Biology of metastasis: studies in renal cancer. In: Principles and Practice of Genitourinary Oncology. Lippincott-Raven Publishers, 1996.
14. Fidler I, Dinney CP , Killion J. Therapy of murine spontaneous renal cancer metastases by coadministration of Liposomes containing macrophage activators and cytokines. In: Hemopoietic Growth Factors and Mononuclear Phagocytes, 148-156, 1993.
15. Dinney CP , Stephenson R. Flow cytometry in urologic oncology. In: Pathophysiologic Principles of Urology. Blackwell Scientific Publications, Inc, 431-454, 1991.

Letters to the Editor

1. Li R, Sylvester R, Dinney CP , Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer 3: 147-148, 2017.
2. McConkey D, Choi W, Dinney CP . Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609-10. Eur Urol 67: e76-8, 2015.